SPOTLIGHT: Auxilium halts Phase III

Auxilium shares this morning sank after it halted a late-stage trial for an injectable enzyme to determine why the freeze-dried material in its vials didn't appear to be correct. Release

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.